前列腺癌根治术后放疗失败模式:两项前瞻性分子影像研究的二次分析
该研究基于两项前瞻性试验,纳入34例根治性前列腺切除及术后放疗后生化复发患者,采用18F-PSMA PET/CT联合mpMRI分析失败模式。32/34例发现PSMA高摄取病灶,其中53.1%为转移性疾病,25.0%为区域复发,21.9%为前列腺窝局部失败;7例局部失败中6例(86%)为野内复发,被100%等剂量线覆盖,剂量64.8-72 Gy。
要点
- 术后放疗后生化复发患者中,远处转移是主要失败模式(53.1%)。
- 约1/5患者出现前列腺窝局部失败,其中86%为野内复发。
- 野内复发被100%等剂量线覆盖,剂量64.8-72 Gy。
核心结论
- 18F-PSMA PET显像有助于识别术后放疗后的隐匿性前列腺癌复发。
- 尽管远处复发为主要失败模式,但约1/5患者出现野内复发,应考量调整术后放疗实践。
研究设计与样本
- 两项前瞻性试验(NCT02190279、NCT03181867)的二次分析,纳入2014年10月至2018年12月间34例根治性前列腺切除及术后放疗后生化复发、常规影像无明确复发灶的患者。
- 采用第一代和第二代18F-PSMA PET显像剂(18F-DCFBC和18F-DCFPyL)联合MRI进行显像。
主要发现
- 32例中17例(53.1%)为转移性疾病,8例(25.0%)为区域复发,7例(21.9%)为前列腺窝局部失败。
- 7例前列腺窝复发中6例(86%)为野内复发,被100%等剂量线覆盖,接受剂量64.8-72 Gy。
- 1例为边缘失败,被49 Gy等剂量线覆盖。
关键数值与推荐
- 前列腺窝野内复发被100%等剂量线覆盖,剂量范围64.8-72 Gy。
- 边缘失败被49 Gy等剂量线覆盖。
临床怎么用
- 对术后放疗后生化复发患者,可考虑18F-PSMA PET/CT联合mpMRI以识别隐匿复发灶。
- 约1/5患者出现前列腺窝野内复发,提示需关注术后放疗靶区与剂量覆盖。
局限性
- 样本量较小(34例)。
- 为两项前瞻性试验的二次分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate Membrane Specific Antigen (PSMA) positron emission tomography (PET) and multiparametric MRI (mpMRI) have shown high accuracy in identifying recurrent lesions after definitive treatment in prostate cancer (PCa). In this study, we aimed to outline patterns of failure in a group of post-prostatectomy patients who received adjuvant or salvage radiation therapy (PORT) and subsequently experienced biochemical recurrence, using 18F-PSMA PET/CT and mpMRI. METHODS: PCa patients with biochemical failure post-prostatectomy, and no evident site of recurrence on conventional imaging, were enrolled on two prospective trials of first and second generation 18F-PSMA PET agents (18F-DCFBC and 18F-DCFPyL) in combination with MRI between October 2014 and December 2018. The primary aim of our study is to characterize these lesions with respect to their location relative to previous PORT field and received dose. RESULTS: A total of 34 participants underwent 18F-PSMA PET imaging for biochemical recurrence after radical prostatectomy and PORT, with 32/34 found to have 18F-PSMA avid lesions. On 18F-PSMA, 17/32 patients (53.1%) had metastatic disease, 8/32 (25.0%) patients had locoregional recurrences, and 7/32 (21.9%) had local failure in the prostate fossa. On further exploration, we noted 6/7 (86%) of prostate fossa recurrences were in-field and were encompassed by 100% isodose lines, receiving 64.8-72 Gy. One patient had marginal failure encompassed by the 49 Gy isodose. CONCLUSIONS: 18F-PSMA PET imaging demonstrates promise in identifying occult PCa recurrence after PORT. Although distant recurrence was the predominant pattern of failure, in-field recurrence was noted in approximately 1/5th of patients. This should be considered in tailoring radiotherapy practice after prostatectomy. Trial registration www.clinicaltrials.gov , NCT02190279 and NCT03181867. Registered July 12, 2014, https://clinicaltrials.gov/ct2/show/NCT02190279 and June 8 2017, https://clinicaltrials.gov/ct2/show/NCT03181867 .
引用
- Rowe LS, Harmon S, Horn A, et al. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques. Radiat Oncol. 2021. PMID: 33568190. doi:10.1186/s13014-020-01733-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。